U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H19N3O4
Molecular Weight 389.404
Optical Activity ( + )
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Tadalafil

SMILES

CN1CC(=O)N2[C@H](CC3=C(NC4=C3C=CC=C4)[C@H]2C5=CC=C6OCOC6=C5)C1=O

InChI

InChIKey=WOXKDUGGOYFFRN-IIBYNOLFSA-N
InChI=1S/C22H19N3O4/c1-24-10-19(26)25-16(22(24)27)9-14-13-4-2-3-5-15(13)23-20(14)21(25)12-6-7-17-18(8-12)29-11-28-17/h2-8,16,21,23H,9-11H2,1H3/t16-,21-/m1/s1

HIDE SMILES / InChI
Molecular Formula C22H19N3O4
Molecular Weight 389.404
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021368s20s21lbl.pdf

Tadalafil is used to treat male erectile dysfunction (impotence) and pulmonary arterial hypertension (PAH). Part of the physiological process of erection involves the release of nitric oxide (NO) in the corpus cavernosum. This then activates the enzyme guanylate cyclase which results in increased levels of cyclic guanosine monophosphate (cGMP), leading to smooth muscle relaxation in the corpus cavernosum, resulting in increased inflow of blood and an erection. Tadalafil is a potent and selective inhibitor of cGMP specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the corpus cavernosum. This means that, with tadalafil on board, normal sexual stimulation leads to increased levels of cGMP in the corpus cavernosum which leads to better erections. Without sexual stimulation and no activation of the NO/cGMP system, tadalafil should not cause an erection.Tadalafil inhibits the cGMP specific phosphodiesterase type 5 (PDE5) which is responsible for degradation of cGMP in the corpus cavernosum located around the penis. Penile erection during sexual stimulation is caused by increased penile blood flow resulting from the relaxation of penile arteries and corpus cavernosal smooth muscle. This response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cGMP in smooth muscle cells. Cyclic GMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum. The inhibition of phosphodiesterase type 5 (PDE5) by tadalafil enhances erectile function by increasing the amount of cGMP. Tadalafil is used for the treatment of erectile dysfunction.

CNS Activity

CNS Active
4002
Curator's Comment: Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD.

Originator

Approval Year

2003
181
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8504
 100.0 µM [IC50]
Inhibitor
8504
 5.1 µM [IC50]
Inhibitor
8504
 0.05 µM [IC50]
Inhibitor
8504
 5.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
CIALIS

Approved Use

CIALIS® is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of: • erectile dysfunction (ED) • the signs and symptoms of benign prostatic hyperplasia (BPH) • ED and the signs and symptoms of BPH (ED/BPH)

Launch Date

2003
Primary
Approved
8583
CIALIS

Approved Use

CIALIS® is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of: • erectile dysfunction (ED) • the signs and symptoms of benign prostatic hyperplasia (BPH) • ED and the signs and symptoms of BPH (ED/BPH)

Launch Date

2003
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
308.1 μg/L
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/29719379
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TADALAFIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
7225 μg × h/L
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/29719379
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TADALAFIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
15 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022332lbl.pdf
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TADALAFIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
17.4 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/29719379
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TADALAFIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
6%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022332lbl.pdf
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TADALAFIL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1946

inhibitor
2252

inducer
1087
inhibitor
2438

inducer
440
inhibitor
2507

inducer
109
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
2153

CYP2C19
2057

CYP2E1
1060
P-gp
2052
CYP1A2
832

CYP2C19
329

CYP2E1
131
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP2C19
2141
 no
CYP2D6
2546
 no
CYP2D6
2546
 no
CYP2E1
1146
 no
CYP2E1
1146
 no
CYP1A2
2333
 no
no (co-administration study)
Comment: taladafil had no clinically significant effect on PK of theophylline
Page: 14.0
CYP1A2
2333
 no
no (co-administration study)
Comment: taladafil had no clinically significant effect on PK of theophylline
Page: 14.0
CYP2C9
2497
 no
no (co-administration study)
Comment: Tadalafil had no clinically significant effect on exposure (AUC) to S-warfarin or R-warfarin, nor did tadalafil affect changes in prothrombin time induced by warfarin.
Page: 14.0
CYP2C9
2497
 no
no (co-administration study)
Comment: Tadalafil had no clinically significant effect on exposure (AUC) to S-warfarin or R-warfarin, nor did tadalafil affect changes in prothrombin time induced by warfarin.
Page: 14.0
CYP3A4
2633
 no
no (co-administration study)
Comment: taladafil had no clinically significant effect on exposure (AUC) to midazolam or lovastatin
Page: 14.0
CYP3A4
2633
 no
no (co-administration study)
Comment: taladafil had no clinically significant effect on exposure (AUC) to midazolam or lovastatin
Page: 14.0
CYP2C19
2141
 not significant [Ki 73 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
1946
 major
yes (co-administration study)
Comment: coadministration with ketoconazole (inhibitor) increased tadalafil exposure by 107%; ritonavir (inhibitor) increased tadalafil AUC by 124%; coadministration with rifampin (inducer) reduced taladafil AUC by 88%;
Page: 49.0
P-gp
2052
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:71940
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:71940
ChemicalBook
CB2236841
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB2236841
eMolecules
29781353
https://www.emolecules.com/cgi-bin/more?vid=29781353
eMolecules
33507691
https://www.emolecules.com/cgi-bin/more?vid=33507691
eMolecules
36754634
https://www.emolecules.com/cgi-bin/more?vid=36754634
MolPort
MolPort-002-885-864
https://www.molport.com/shop/molecule-link/MolPort-002-885-864
Selleck Chemicals
Tadalafil(Cialis)
http://www.selleckchem.com/products/Tadalafil(Cialis).html
ZINC
ZINC000003993855
http://zinc15.docking.org/substances/ZINC000003993855
PubMed

PubMed

TitleDatePubMed
Nocturnal electrobioimpedance volumetric assessment in diabetic men with erectile dysfunction before and after tadalafil intake.
2004-10
Interactions between cGMP- and cAMP-pathways are involved in the regulation of penile smooth muscle tone.
2004-10
[Erectile dysfunction. New drugs with special consideration of the PDE 5 inhibitors].
2004-07
Time course of the interaction between tadalafil and nitrates.
2004-06-02
The efficacy and safety of tadalafil: an update.
2004-06
Re: tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones.
2004-06
Emerging oral drugs for erectile dysfunction.
2004-05
New drugs of 2003.
2004-04-22
Sexual dysfunction and diabetes.
2004-04
[Comparison of efficacy and safety of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction].
2004-04
Gateways to clinical trials.
2004-04
Tadalafil and vardenafil.
2004-04
Novel phosphodiesterase type 5 inhibitors: assessing hemodynamic effects and safety parameters.
2004-04
Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles.
2004-04
Pills for erectile dysfunction: now there are three.
2004-04
Treatment of erectile dysfunction.
2004-04
A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil.
2004-04
Atazanavir (Reyataz): new recommendations if combined with tenofovir (Viread) -- and warning on Viagra, Cialis, and Levitra.
2004-03-26
Third drug for impotence.
2004-03-23
Pharmacokinetics, pharmacodynamics, and efficacy of phosphodiesterase type 5 inhibitors.
2004-03
Therapeutic options for patients returning to sexual activity.
2004-03
Gateways to clinical trials.
2004-03
Long-term safety and tolerability of tadalafil in the treatment of erectile dysfunction.
2004-03
[Treatment of erectile dysfunction].
2004-02-29
Cialis is here. The soft sell.
2004-02-02
Tadalafil (Cialis) and vardenafil (Levitra) recently approved drugs for erectile dysfunction.
2004-02
[Erectile dysfunction. Epidemiology, physiology, etiology, diagnosis and therapy].
2004-02
Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy.
2004-02
[Efficacy and safety of the application of cialis for erectile dysfunction].
2004-01-08
Are they better than Viagra? Two new drugs for erectile dysfunction work like Viagra and carry similar risks and benefits. Their subtle differences, however, may make a difference for some men.
2004-01
Tadalafil (cialis) for erectile dysfunction.
2003-12-22
Novel PDE5 inhibitors for the treatment of male erectile dysfunction.
2003-12-06
Tadalafil: new preparation. Slightly more convenient, but poorly assessed in organic disorders.
2003-12
Oral drug treatment of erectile dysfunction.
2003-12
Tadalafil in the treatment of erectile dysfunction.
2003-12
Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists.
2003-12
Tadalafil for the treatment of erectile dysfunction.
2003-12
Time course of the interaction between tadalafil and nitrates.
2003-11-19
[Pleasure and pain in sexual relations. The basis and reasons for sex counseling by the general practitioner].
2003-11-13
Roundtable discussion: tadalafil study group.
2003-11-06
Cardiovascular effects of tadalafil in patients on common antihypertensive therapies.
2003-11-06
Cardiovascular effects of tadalafil.
2003-11-06
Efficacy and tolerability of tadalafil, a novel phosphodiesterase 5 inhibitor, in treatment of erectile dysfunction.
2003-11-06
Overview of phosphodiesterase 5 inhibition in erectile dysfunction.
2003-11-06
Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference.
2003-11
A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction.
2003-11
Review of tadalafil in the treatment of erectile dysfunction.
2003-11
Therapy of ED: PDE-5 Inhibitors.
2003-09-15
[Medication of the month. Vardenafil (Levitra)].
2003-09
Effects of tadalafil on erectile dysfunction in men with diabetes.
2003-08
Patents

Patents

JP2008520751A
1
JP2013241463A
1

Sample Use Guides

In Vivo Use Guide
ED: Starting dose: 10 mg as needed prior to sexual activity. Increase to 20 mg or decrease to 5 mg based upon efficacy/tolerability. Improves erectile function compared to placebo up to 36 hours post dose. Not to be taken more than once per day
Route of Administration: Oral
In Vitro Use Guide
Increasing levels of tadalafil (1–25 uM) attenuated proliferation of human primary prostatic stromal cells (PrSCs) in a dose-dependent manner with concentrations above 5 uM showing highly significant effects
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:08:29 GMT 2025
Edited
by admin
on Mon Mar 31 18:08:29 GMT 2025
Record UNII
742SXX0ICT
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CHEWTADZY
Preferred Name English
Tadalafil
EMA EPAR   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
(6R,12aR)-6-(1,3-Benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methylpyrazino[1?,2?:1,6]pyrido[3,4-b]indole-1,4-dione
Systematic Name English
TADALAFIL [HSDB]
Common Name English
TRANS-TADALAFIL
Common Name English
TADALAFIL [MART.]
Common Name English
TADALAFIL [USP MONOGRAPH]
Common Name English
TADALAFIL [JAN]
Common Name English
Pyrazino[1?,2?:1,6]pyrido[3,4-b]indole-1,4-dione, 6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6R,12aR)-
Systematic Name English
CIALIS
Brand Name English
TADALAFIL [MI]
Common Name English
Tadalafil [WHO-DD]
Common Name English
LY-450190
Code English
TADALAFIL [EP MONOGRAPH]
Common Name English
TADALAFIL [EMA EPAR]
Common Name English
OPSYNVI COMPONENT TADALAFIL
Brand Name English
LY450190
Code English
TADALAFIL [USP-RS]
Common Name English
NSC-759172
Code English
TADALAFIL MYLAN
Brand Name English
TADALAFIL [USAN]
Common Name English
tadalafil [INN]
Common Name English
TADALAFIL [VANDF]
Common Name English
NSC-750236
Code English
Pyrazino[1?,2?:1,6]pyrido[3,4-b]indole-1,4-dione, 6-(1,3-benzodioxol-5-yl)-2,3,6,7,12,12a-hexahydro-2-methyl-, (6R-trans)-
Systematic Name English
IC351
Code English
TADALAFIL [ORANGE BOOK]
Common Name English
IC-351
Code English
ENTADFI COMPONENT TADALAFIL
Brand Name English
Classification Tree Code System Code
WHO-ATC C02KX52
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
FDA ORPHAN DRUG 528316
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
EMA ASSESSMENT REPORTS CIALIS (AUTHORIZED: ERECTILE DYSFUNCTIONS)
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
NDF-RT N0000175599
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
EMA ASSESSMENT REPORTS ADCIRCA (AUTHORIZED: HYPERTENSION, PULMONARY)
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
NDF-RT N0000020026
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
FDA ORPHAN DRUG 476415
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
EMA ASSESSMENT REPORTS TADALAFIL MYLAN (AUTHORIZED: ERECTILE DYSFUNCTIONS)
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
FDA ORPHAN DRUG 228206
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
NCI_THESAURUS C2127
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
WHO-VATC QG04BE08
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
FDA ORPHAN DRUG 509615
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
WHO-ATC G04BE08
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
LIVERTOX NBK547910
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
Code System Code Type Description
CAS
171596-29-5
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
PRIMARY
NSC
750236
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
PRIMARY
INN
8136
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
PRIMARY
IUPHAR
7299
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
PRIMARY
SMS_ID
100000089310
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
PRIMARY
RS_ITEM_NUM
1642879
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
PRIMARY
HSDB
7303
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
PRIMARY
NSC
759172
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
PRIMARY
RXCUI
358263
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
PRIMARY RxNorm
LACTMED
Tadalafil
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
PRIMARY
MESH
C429886
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
PRIMARY
FDA UNII
742SXX0ICT
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
PRIMARY
DRUG BANK
DB00820
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
PRIMARY
PUBCHEM
110635
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
PRIMARY
EVMPD
SUB12602MIG
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
PRIMARY
ChEMBL
CHEMBL779
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
PRIMARY
NCI_THESAURUS
C47743
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
PRIMARY
USAN
LL-07
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
PRIMARY
MERCK INDEX
m10427
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
PRIMARY Merck Index
CHEBI
71940
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
PRIMARY
EPA CompTox
DTXSID9046786
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
PRIMARY
DAILYMED
742SXX0ICT
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
PRIMARY
DRUG CENTRAL
2553
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
PRIMARY
WIKIPEDIA
TADALAFIL
Created by admin on Mon Mar 31 18:08:29 GMT 2025 , Edited by admin on Mon Mar 31 18:08:29 GMT 2025
PRIMARY
Related Record Type Details
Structure of Tadalafil
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
Structure of Tadalafil
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
MAJOR
Related Record Type Details
Structure of TADALAFIL 3-METHYL-4-GLUCURONIDE CATECHOL
METABOLITE -> PARENT
MAJOR
URINE
Structure of TADALAFIL 3-METHYL CATECHOL
METABOLITE -> PARENT
Related Record Type Details
Structure of 6'-(1,3-BENZODIOXOL-5-YL)-2'-METHYL-2',3',8',8A'-TETRAHYDRO-6'H-SPIRO(3,1-BENZOXAZINE-4,7'-PYRROLO(1,2-A)PYRAZINE)-1',2,4'(1H)-TRIONE, (8A'R)-
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of Tadalafil, (6S,12aS)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 6'-(1,3-BENZODIOXOL-5-YL)-2'-METHYL-2',3',8',8A'-TETRAHYDRO-6'H-SPIRO(INDOLE-3,7'-PYRROLO(1,2-A)PYRAZINE)-1',2,4'(1H)-TRIONE, (8A'R)-
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of Tadalafil, (6S,12aR)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of Tadalafil, (6S,12aR)-
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of Ethyl (1R,3R)-1-(1,3-benzodioxol-5-yl)-2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylate
IMPURITY -> PARENT
Structure of TADALAFIL KETOLACTAM
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of 12-(1,3-BENZODIOXOL-5-YL)-12A-HYDROXY-8-METHYL-6A,6B,8,9,12,12A-HEXAHYDROPYRAZINO(1',2';:1,2)PYRROLO(3,4-C)QUINOLINE-6,7,10(5H)-TRIONE, (6BR)-
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of 6-(1,3-BENZODIOXOL-5-YL)-6A-HYDROXY-2-METHYL-2,3,6A,7,12A,12B-HEXAHYDROPYRAZINO(1',2':1,5)PYRROLO(3,4-B)QUINOLINE-1,4,12(6H)-TRIONE, (6R,12AR,12BR)-
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of 6-(1,3-BENZODIOXOL-5-YL)-12-HYDROXY-2-METHYL-2,3,6,12B-TETRAHYDROPYRAZINO(1',2':1,5)PYRROLO(3,4-B)QUINOLINE-1,4-DIONE, (12BR)-
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of Tadalafil, (6R,12aS)-
IMPURITY -> PARENT
ASSAY (HPLC)
EP
Structure of Tadalafil, (6S,12aS)-
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of Tadalafil, (6R,12aS)-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
Structure of Tadalafil
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Tmax PHARMACOKINETIC SINGLE ORAL ADMINISTRATION

Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966